Filing Details
- Accession Number:
- 0001209191-16-137609
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-08-17 17:38:50
- Reporting Period:
- 2016-08-16
- Filing Date:
- 2016-08-17
- Accepted Time:
- 2016-08-17 17:38:50
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
906709 | Nektar Therapeutics | NKTR | Pharmaceutical Preparations (2834) | 943134940 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1443159 | Maninder Hora | C/O Nektar Therapeutics 455 Mission Bay Boulevard South San Francisco CA 94158 | Svp Pharma Dev & Mfg Ops | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2016-08-16 | 3,305 | $17.56 | 51,997 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- This transaction was executed in multiple trades at prices ranging from $17.47 to $17.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
- The total holdings include the remaining portion of the 26,000 shares of restricted stock units ("RSUs") that were previously reported in Table II for the reporting person and which are being reclassified to Table I. These RSUs were granted on December 15, 2015, are convertible on a one-for-one basis into shares of Common Stock of the Company, and vest on a quarterly pro-rata basis over a period of three (3) years from the date of grant.
- This number includes 5,000 shares held by the reporting person in his account under the Issuer's ESPP. The acquisition of these shares under that plan is exempt under Rule 16b-3(c).